Dr. Stephen Strom is a Professor at the Karolinska Institutet in the Department of Laboratory Medicine of the Division of Pathology, Stockholm, Sweden. He also holds a joint appointment in the Division of Cellular and Molecular Pathology at the University of Pittsburgh.
Dr. Strom started his research career in the Department of Pharmacology at the University of Kansas Medical Center, Kansas City, Kansas, where he studied the effects of cancer chemotherapeutic agents on bone marrow colony-forming stem cells. He understood very quickly that it might be easier to prevent cancer than to cure it so in 1978 he chose to do postdoctoral work at Duke University under George Michalopoulos, MD, PhD, a well known researcher in liver regeneration, where he studied chemical carcinogenesis. In order to make the data relevant to humans, Dr. Strom developed techniques to isolate hepatocytes from human liver tissue to identify how human liver cells metabolized chemical carcinogens. Dr. Strom worked at Duke University for a total of 10 years first as a postdoctoral fellow and subsequently as an Assistant Professor.
In 1988 he moved to Virginia Commonwealth University, Richmond, Virginia, where he and a transplant surgeon, Dr. Robert Fisher, began to make plans to transplant hepatocytes into patients to treat liver disease. In late 1991 and 1992, Drs. Strom and Fisher were the first to transplant patients with liver disease with allogeneic hepatocyte transplantation.
Dr. Strom then moved to Pittsburgh in 1993 and his laboratory was the first in the US to receive FDA (Food and Drug Administration) approval for the isolation of hepatocytes for clinical transplants. Dr. Strom’s laboratory continued to serve as a hepatocyte bank for transplants at five different Medical Centers in the US. He and his colleagues have transplanted over 30 patients with different types of liver disease.
In 2013, Dr. Strom moved to Sweden and is the Torsten och Ragnar Söderberg Professor in Cell Transplantation and Regenerative Medicine. At the Karolinska Institutet he is the principal investigator for a Strategic Research Program in Cancer (StratCan) and the Vetenskaprådet (Swedish Research Council) study entitled, “Understanding the biology of genes associated with longevity and healthy aging using humanized mouse models.” His work also includes a European Commission study entitled, “HUMAN: Health and understanding of metabolism, aging and nutrition.”
Dr. Strom’s research interests include:
hepatocyte transplantation as a clinical treatment of liver disease
expression and regulation of drug metabolizing enzymes and in human liver
regulation of human hepatocyte replication and differentiation
production of hepatocytes for transplantation from stem or progenitor cells